Find Terbinafine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

69RELATED EXCIPIENT COMPANIES

116EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 91161-71-6, Lamisil, Lamasil, (e)-n,6,6-trimethyl-n-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine, Sf-86-327, Lamisil at
Molecular Formula
C21H25N
Molecular Weight
291.4  g/mol
InChI Key
DOMXUEMWDBAQBQ-WEVVVXLNSA-N
FDA UNII
G7RIW8S0XP

Terbinafine
A naphthalene derivative that inhibits fungal SQUALENE EPOXIDASE and is used to treat DERMATOMYCOSES of the skin and nails.
Terbinafine is an Allylamine Antifungal.
1 2D Structure

Terbinafine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine
2.1.2 InChI
InChI=1S/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3/b9-5+
2.1.3 InChI Key
DOMXUEMWDBAQBQ-WEVVVXLNSA-N
2.1.4 Canonical SMILES
CC(C)(C)C#CC=CCN(C)CC1=CC=CC2=CC=CC=C21
2.1.5 Isomeric SMILES
CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21
2.2 Other Identifiers
2.2.1 UNII
G7RIW8S0XP
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (e)-n-(6,6-dimethyl-2-heptenynyl)-n-methyl-1-naphthalenementhamin Hydrochloride

2. Da 5505

3. Lamisil

4. Sf 86 327

5. Sf 86-327

6. Sf 86327

7. Sf-86-327

8. Sf86327

9. Tdt 067

10. Tdt-067

11. Tdt067

12. Terbinafine Hydrochloride

13. Terbinafine, (z)-

14. Terbinafine, (z)-isomer

2.3.2 Depositor-Supplied Synonyms

1. 91161-71-6

2. Lamisil

3. Lamasil

4. (e)-n,6,6-trimethyl-n-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine

5. Sf-86-327

6. Lamisil At

7. Sf 86-327

8. Terbinafin

9. Terbinex

10. (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthalenemethylamine

11. Terbinafina

12. (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthalene Methanamine

13. Terbinafine Free Base

14. Tdt-067

15. G7riw8s0xp

16. Chembl822

17. Chebi:9448

18. Lamisil Tablet

19. 91161-71-6 (free Base)

20. Terbinafinum

21. Zabel

22. 1-naphthalenemethanamine, N-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-, (e)-

23. Ncgc00159346-02

24. (2e)-n,6,6-trimethyl-n-(1-naphthylmethyl)hept-2-en-4-yn-1-amine

25. (2e)-n,6,6-trimethyl-n-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine

26. Dsstox_cid_3640

27. N-[(2e)-6,6-dimethyl-2-hepten-4-yn-1-yl]-n-methyl-1-naphthalenemethanamine

28. Dsstox_rid_77123

29. Dsstox_gsid_23640

30. Lamasil (tn)

31. Cas-91161-71-6

32. Unii-g7riw8s0xp

33. Terbinafine (usan/inn)

34. Brn 4256376

35. Corbinal

36. Terbinafine [usan:inn:ban]

37. N,6,6-trimethyl-n-(1-naphthylmethyl)hept-2-en-4-yn-1-amine Hydrochloride

38. Erbinafine Hydrochloride

39. Terbinafine [mi]

40. Terbinafine, Sf-86-327, Lamisil, Tbnf

41. Terbinafine [inn]

42. Terbinafine [usan]

43. Ec 618-706-8

44. Terbinafine [vandf]

45. Terbinafine [mart.]

46. Schembl36794

47. Schembl37843

48. Terbinafine [who-dd]

49. Mls006011885

50. Bidd:gt0825

51. Dtxsid2023640

52. Terbinafine (lamisil, Terbinex)

53. Terbinafine [green Book]

54. Chebi:94705

55. Terbinafine [orange Book]

56. Hms2089b20

57. Hms3715l08

58. Albb-027269

59. Bcp22896

60. Osurnia Component Terbinafine

61. Zinc1530981

62. Tox21_111591

63. (e)-n,6,6-trimethyl-n-(1-naphthylmethyl)hept-2-en-4-yn-1-amine

64. Bbl010959

65. Bdbm50018518

66. Hy-17395a

67. Mfcd00242672

68. S1725

69. Stk802069

70. Akos001451917

71. Tox21_111591_1

72. Ac-8561

73. Ccg-221253

74. Cs-1944

75. Db00857

76. Gs-3099

77. Terbinafine Component Of Osurnia

78. (e)-n,6,6-trimethyl-n-(naphthalen-1

79. Ncgc00159346-03

80. Ncgc00159346-04

81. Ncgc00188975-01

82. Terbinafine [ema Epar Veterinary]

83. Sf86-327

84. Smr004703509

85. Sbi-0206829.p001

86. Sw197656-3

87. T3677

88. C08079

89. D02375

90. Ab00698510-07

91. Ab00698510-09

92. Ab00698510-10

93. Ab00698510-11

94. Ab00698510_12

95. Ab00698510_13

96. Ab00698510_14

97. 161t716

98. A843743

99. Q415259

100. Brd-k68132782-003-05-4

101. (6,6-dimethyl-hept-2-en-4-ynyl)-methyl-naphthalen-1-ylmethyl-amine

102. N,6,6-trimethyl-n-(1-naphthylmethyl)-2-heptene-4-yne-1-amine

103. Sf 86-327; Sf-86-327; Sf86-327; Lamasil; Lamisil At

104. ((e)-6,6-dimethyl-hept-2-en-4-ynyl)-methyl-naphthalen-1-ylmethyl-amine

105. 1n,6,6-trimethyl-1n-(1-naphthylmethyl)-(e)-2-hepten-4-yn-1-amine

106. (6,6-dimethyl-hept-2-en-4-ynyl)-methyl-naphthalen-1-ylmethyl-amine(terbinafine)

107. (6,6-dimethylhept-2-en-4-yn-1-yl)methyl(1-naphthylmethyl)amine Hydrochloride

108. [(2e)-6,6-dimethylhept-2-en-4-yn-1-yl](methyl)[(naphthalen-1-yl)methyl]amine

109. [(e)-6,6-dimethyl-hept-2-en-4-ynyl]-methyl-(naphthalen-1-yl-methyl)-amine

110. 1-naphthalenemethanamine, N-[(2e)-6,6-dimethyl-2-hepten-4-yn-1-yl]-n-methyl-

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 291.4 g/mol
Molecular Formula C21H25N
XLogP35.6
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count1
Rotatable Bond Count5
Exact Mass291.198699802 g/mol
Monoisotopic Mass291.198699802 g/mol
Topological Polar Surface Area3.2 Ų
Heavy Atom Count22
Formal Charge0
Complexity428
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 4  
Drug NameLamisil
PubMed HealthTerbinafine
Drug ClassesAntifungal
Drug LabelLamisil Tablets contain the synthetic allylamine antifungal compound terbinafine hydrochloride.Chemically, terbinafine hydrochloride is (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine hydrochloride. The empirical formula C21H26...
Active IngredientTerbinafine hydrochloride
Dosage FormTablet; Cream; Granule
RouteOral; Topical
Strengtheq 187.5mg base/packet; 1%; eq 250mg base; eq 125mg base/packet
Market StatusOver the Counter; Prescription
CompanyNovartis

2 of 4  
Drug NameLamisil at
Active IngredientTerbinafine hydrochloride; Terbinafine
Dosage FormSpray; Gel; Solution
RouteTopical
Strength1%
Market StatusOver the Counter
CompanyNovartis

3 of 4  
Drug NameLamisil
PubMed HealthTerbinafine
Drug ClassesAntifungal
Drug LabelLamisil Tablets contain the synthetic allylamine antifungal compound terbinafine hydrochloride.Chemically, terbinafine hydrochloride is (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine hydrochloride. The empirical formula C21H26...
Active IngredientTerbinafine hydrochloride
Dosage FormTablet; Cream; Granule
RouteOral; Topical
Strengtheq 187.5mg base/packet; 1%; eq 250mg base; eq 125mg base/packet
Market StatusOver the Counter; Prescription
CompanyNovartis

4 of 4  
Drug NameLamisil at
Active IngredientTerbinafine hydrochloride; Terbinafine
Dosage FormSpray; Gel; Solution
RouteTopical
Strength1%
Market StatusOver the Counter
CompanyNovartis

4.2 Drug Indication

Terbinafine hydrochloride is indicated to treat fungal skin and nail infections caused by _Trichophyton_ species, _Microsporum canis_, _Epidermophyton floccosum_, and _Tinea_ species. Terbinafine hydrochloride also treats yeast infections of the skin caused by _Candida_ species and _Malassezia furfur_.


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

Terbinafine is an allylamine antifungal that inhibits squalene epoxidase (also known as squalene monooxygenase) to prevent the formation of ergosterol and cause an accumulation of squalene, weakening the cell wall of fungal cells. Terbinafine distributes into tissues and has a long terminal elimination half life, so the duration of action is long. Overdose with terbinafine is rare, even above the therapeutic dose, so the therapeutic index is wide. Patients taking oral terbinafine should have liver function tests performed prior to treatment to reduce the risk of liver injury.


5.2 MeSH Pharmacological Classification

Antifungal Agents

Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)


Enzyme Inhibitors

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
TERBINAFINE
5.3.2 FDA UNII
G7RIW8S0XP
5.3.3 Pharmacological Classes
Allylamine [CS]; Allylamine Antifungal [EPC]
5.4 ATC Code

D - Dermatologicals

D01 - Antifungals for dermatological use

D01A - Antifungals for topical use

D01AE - Other antifungals for topical use

D01AE15 - Terbinafine


D - Dermatologicals

D01 - Antifungals for dermatological use

D01B - Antifungals for systemic use

D01BA - Antifungals for systemic use

D01BA02 - Terbinafine


5.5 Absorption, Distribution and Excretion

Absorption

Oral terbinafine is >70% absorbed but only 40% bioavailable after first pass metabolism, reaching a Cmax of 1g/mL with a Tmax of 2 hours an an AUC of 4.56g\*h/mL. Over the course of a week, 1% topical terbinafine's Cmax increases from 949-1049ng/cm2 and the AUC increases from 9694-13,492ng/cm2/h.


Route of Elimination

Terbinafine is approximately 80% eliminated in urine, while the remainder is eliminated in feces. The unmetabolized parent drug is not present in urine.


Volume of Distribution

A single 250mg oral dose of terbinafine has a volume of distribution at steady state of 947.5L or 16.6L/kg.


Clearance

A single 250mg oral dose of terbinafine has a clearance of 76L/h or 1.11L/h/kg.


5.6 Metabolism/Metabolites

Terbinafine can be deaminated to 1-naphthaldehyde by CYP2C9, 2B6, 2C8, 1A2, 3A4, and 2C19. 1-naphthaldehyde is then oxidized to 1-naphthoic acid or reduced to 1-naphthalenemethanol. Terbinafine can also be hydroxylated by CYP1A2, 2C9, 2C8, 2B6, and 2C19 to hydroxyterbinafine. Hydroxyterbinafine is then oxidized to carboxyterbinafine or N-demethylated by CYP3A4, 2B6, 1A2, 2C9, 2C8, and 2C19 to desmethylhydroxyterbinafine. Terbinafine can be N-demethylated to desmethylterbinafine. Desmethylterbinafine is then dihydroxylated to a desmethyldihydrodiol or hydroxylated to desmethylhydroxyterbinafine. Finally, terbinafine can be dihydroxylated to a dihydrodiol which is then N-demethylated to a desmethyldihydrodiol.


Terbinafine has known human metabolites that include 1-Naphtaldehyde, Hydroxyterbinafine, and N-Desmethylterbinafine.

S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560


5.7 Biological Half-Life

Oral terbinafine has an effective half life of approximately 36 hours. However, the terminal half life ranges from 200-400 hours as it distributes into skin and adipose tissue. 1% topical terbinafine's half life increases over the first seven days from approximately 10-40 hours.


5.8 Mechanism of Action

Terbinafine inhibits the enzyme squalene monooxygenase (also called squalene epoxidase), preventing the conversion of squalene to 2,3-oxydosqualene, a step in the synthesis of ergosterol. This inhibition leads to decreased ergosterol, which would normally be incorporated into the cell wall, and accumulation of squalene. Generation of a large number of squalene containing vesicles in the cytoplasm may leach other lipids away from, and further weaken, the cell wall.


API SUPPLIERS

read-more
read-more

01

Olon S.p.A

Italy

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Olon S.p.A

Italy

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

02

Novartis Pharmaceuticals Corporati...

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Novartis Pharmaceuticals Corporati...

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF arrow-down VMF Others AUDIT
blank

03

F.I.S. Fabbrica Italiana Sintetici

Italy

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

F.I.S. Fabbrica Italiana Sintetici

Italy

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

04

Skanttr Lifescience

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Skanttr Lifescience

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

05

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF CEP/COS JDMF EU-WCarrow-down NDC KDMF VMF Others AUDIT arrow-down
blank

06

Angels Pharma India Private Limite...

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

07

Inist

South Korea

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Inist

South Korea

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF arrow-down VMF Others AUDIT
blank

08

HELM Portugal

Portugal

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

HELM Portugal

Portugal

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

Chromo Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Chromo Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF CEP/COS JDMF EU-WCarrow-down NDC KDMF VMF Others AUDIT arrow-down
blank

10

Shamrock Medicaments

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Shamrock Medicaments

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

PEGS Boston Summit
Not Confirmed

01

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 20266

Submission : 2007-01-29

Status : Inactive

Type : II

blank

02

Novartis Pharmaceuticals Corp

Switzerland

USDMF

arrow
PEGS Boston Summit
Not Confirmed

02

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 27059

Submission : 2013-06-07

Status : Active

Type : II

blank

03

Olon Spa

Italy

USDMF

arrow
PEGS Boston Summit
Not Confirmed

03

Olon Spa

Italy
arrow
PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 33058

Submission : 2019-06-18

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Terbinafine HCL USP/Ph. Eur

Date of Issue : 2024-07-18

Valid Till : 2027-06-07

Written Confirmation Number : WC-0317

Address of the Firm : Plot No. 43 & 44, IDA Phase-ll, Pashamylaram, Pashamylaram(V), Patancheru (M), S...

blank

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Terbinafine IH

Date of Issue : 2025-07-07

Valid Till : 2028-07-14

Written Confirmation Number : WC-0021

Address of the Firm : Sy. Nos, 317,320,321,322,323,604 & 605, Pincode-502329, Rudraram (Village), Pata...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Terclara (terbinafine) is a topical formulation of terbinafine which is approved for the treatment of mild to moderate fungal infections in nail and nail bed (Onychomycosis).


Lead Product(s): Terbinafine,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Terclara

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 03, 2025

blank

01

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Terclara (terbinafine) is a topical formulation of terbinafine which is approved for the treatment of mild to moderate fungal infections in nail and nail bed (Onychomycosis).

Product Name : Terclara

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 03, 2025

blank

Details:

Terclara (terbinafine) is a topical squalene monooxygenase inhibitor antifungal drug candidate, which is launched in Sweden for the treatment of onychomycosis.


Lead Product(s): Terbinafine,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Terclara

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 13, 2024

blank

02

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Terclara (terbinafine) is a topical squalene monooxygenase inhibitor antifungal drug candidate, which is launched in Sweden for the treatment of onychomycosis.

Product Name : Terclara

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 13, 2024

blank

Details:

MOB-015 is a topical formulation of terbinafine which is approved for the treatment of mild to moderate fungal infections in nail and nail bed(Onychomycosis).


Lead Product(s): Terbinafine,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Terclara

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 07, 2024

blank

03

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : MOB-015 is a topical formulation of terbinafine which is approved for the treatment of mild to moderate fungal infections in nail and nail bed(Onychomycosis).

Product Name : Terclara

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 07, 2024

blank

Details:

Terclara (terbinafine) is a topical squalene monooxygenase inhibitor antifungal drug candidate, which is launched in Sweden for the treatment of onychomycosis.


Lead Product(s): Terbinafine,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Terclara

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 07, 2024

blank

04

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Terclara (terbinafine) is a topical squalene monooxygenase inhibitor antifungal drug candidate, which is launched in Sweden for the treatment of onychomycosis.

Product Name : Terclara

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 07, 2024

blank
  • Development Update

Details:

Terbinafine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Onychomycosis.


Lead Product(s): Terbinafine,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 26, 2021

blank

05

Hallux

Country
arrow
PEGS Boston Summit
Not Confirmed

Hallux

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Terbinafine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Onychomycosis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 26, 2021

blank

Details:

The agreement with Allderma complements the existing licensing agreement for MOB-015 in Europe. Allderma is responsible for marketing, distribution and sales in Sweden, Denmark and Norway, while Moberg Pharma is responsible for the manufacture and delivery of the product.


Lead Product(s): Terbinafine,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Terclara

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Allderma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration November 08, 2021

blank

06

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : The agreement with Allderma complements the existing licensing agreement for MOB-015 in Europe. Allderma is responsible for marketing, distribution and sales in Sweden, Denmark and Norway, while Moberg Pharma is responsible for the manufacture and delive...

Product Name : Terclara

Product Type : Miscellaneous

Upfront Cash : Undisclosed

November 08, 2021

blank

Details:

Resilia is proud to offer patients an effective and safe product like Solace Cream, previously available by prescription. Solace Cream is formulated to help control eczema flares and keep future eczema flares dormant longer by utilizing essential skin building blocks.


Lead Product(s): Terbinafine,Inapplicable

Therapeutic Area: Dermatology Brand Name: Solace

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Pelle Ventures

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition October 25, 2021

blank

07

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Resilia is proud to offer patients an effective and safe product like Solace Cream, previously available by prescription. Solace Cream is formulated to help control eczema flares and keep future eczema flares dormant longer by utilizing essential skin bu...

Product Name : Solace

Product Type : Miscellaneous

Upfront Cash : Undisclosed

October 25, 2021

blank

Details:

MOB-015 is our next-generation nail fungus treatment targeting both over-the-counter (OTC) and prescription markets around the world. The company's timeline remains, with planned submission for MOB-015 in Europe this year and expected market approval in 2023.


Lead Product(s): Terbinafine,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Terclara

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 22, 2021

blank

08

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : MOB-015 is our next-generation nail fungus treatment targeting both over-the-counter (OTC) and prescription markets around the world. The company's timeline remains, with planned submission for MOB-015 in Europe this year and expected market approval in ...

Product Name : Terclara

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 22, 2021

blank

Details:

The proceeds will be used for registration activities and clinical work for MOB-015. When the Rights Issue is completed, the Company intends to terminate the current Convertible Loan Agreement.


Lead Product(s): Terbinafine,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Terclara

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: $17.5 million Upfront Cash: Undisclosed

Deal Type: Financing November 06, 2020

blank

09

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : The proceeds will be used for registration activities and clinical work for MOB-015. When the Rights Issue is completed, the Company intends to terminate the current Convertible Loan Agreement.

Product Name : Terclara

Product Type : Miscellaneous

Upfront Cash : Undisclosed

November 06, 2020

blank

Details:

MOB-015's superior mycological cure (percentage of patients who were fungus free) has now been demonstrated in two pivotal studies, providing further support for the company's target to make MOB-015 the future market leader in onychomycosis.


Lead Product(s): Terbinafine,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Terclara

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 14, 2020

blank

10

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : MOB-015's superior mycological cure (percentage of patients who were fungus free) has now been demonstrated in two pivotal studies, providing further support for the company's target to make MOB-015 the future market leader in onychomycosis.

Product Name : Terclara

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 14, 2020

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

read-more
read-more

Controlled & Modified Release

read-more
read-more

Topical

read-more
read-more

Solubilizers

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Emulsifying Agents

read-more
read-more

Parenteral

read-more
read-more

Empty Capsules

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Vegetarian Capsules

read-more
read-more

API Stability Enhancers

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Taste Masking

read-more
read-more

Granulation

read-more
read-more

Coloring Agents

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Direct Compression

read-more
read-more

Rheology Modifiers

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

Health Canada Patents

read-more
read-more

01

arrow
PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed

Terbinafine

Brand Name : LAMISIL

Patent Number : 2068957

Filing Date : 1992-05-19

Strength per Unit : 1%

Dosage Form : Gel

Human Or VET : Human

Route of Administration : Topical

Patent Expiration Date : 2012-05-19

Date Granted : 2002-12-17

blank

02

arrow
PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed

Terbinafine

Brand Name : LAMISIL

Patent Number : 2052229

Filing Date : 1991-09-25

Strength per Unit : 1%

Dosage Form : Gel

Human Or VET : Human

Route of Administration : Topical

Patent Expiration Date : 2011-09-25

Date Granted : 2004-03-09

blank

03

arrow
PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed

Terbinafine

Brand Name : LAMISIL

Patent Number : 2062341

Filing Date : 1992-03-05

Strength per Unit : 1%

Dosage Form : Gel

Human Or VET : Human

Route of Administration : Topical

Patent Expiration Date : 2012-03-05

Date Granted : 2004-05-11

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ANALYTICAL

Upload your methods for free, ask us

ABOUT THIS PAGE

Looking for 91161-71-6 / Terbinafine API manufacturers, exporters & distributors?

Terbinafine manufacturers, exporters & distributors 1

98

PharmaCompass offers a list of Terbinafine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Terbinafine manufacturer or Terbinafine supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Terbinafine manufacturer or Terbinafine supplier.

API | Excipient name

Terbinafine

Synonyms

91161-71-6, Lamisil, Lamasil, (e)-n,6,6-trimethyl-n-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine, Sf-86-327, Lamisil at

Cas Number

91161-71-6

Unique Ingredient Identifier (UNII)

G7RIW8S0XP

About Terbinafine

A naphthalene derivative that inhibits fungal SQUALENE EPOXIDASE and is used to treat DERMATOMYCOSES of the skin and nails.

Terbinex Manufacturers

A Terbinex manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Terbinex, including repackagers and relabelers. The FDA regulates Terbinex manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Terbinex API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Terbinex manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Terbinex Suppliers

A Terbinex supplier is an individual or a company that provides Terbinex active pharmaceutical ingredient (API) or Terbinex finished formulations upon request. The Terbinex suppliers may include Terbinex API manufacturers, exporters, distributors and traders.

click here to find a list of Terbinex suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Terbinex USDMF

A Terbinex DMF (Drug Master File) is a document detailing the whole manufacturing process of Terbinex active pharmaceutical ingredient (API) in detail. Different forms of Terbinex DMFs exist exist since differing nations have different regulations, such as Terbinex USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Terbinex DMF submitted to regulatory agencies in the US is known as a USDMF. Terbinex USDMF includes data on Terbinex's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Terbinex USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Terbinex suppliers with USDMF on PharmaCompass.

Terbinex KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Terbinex Drug Master File in Korea (Terbinex KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Terbinex. The MFDS reviews the Terbinex KDMF as part of the drug registration process and uses the information provided in the Terbinex KDMF to evaluate the safety and efficacy of the drug.

After submitting a Terbinex KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Terbinex API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Terbinex suppliers with KDMF on PharmaCompass.

Terbinex WC

A Terbinex written confirmation (Terbinex WC) is an official document issued by a regulatory agency to a Terbinex manufacturer, verifying that the manufacturing facility of a Terbinex active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Terbinex APIs or Terbinex finished pharmaceutical products to another nation, regulatory agencies frequently require a Terbinex WC (written confirmation) as part of the regulatory process.

click here to find a list of Terbinex suppliers with Written Confirmation (WC) on PharmaCompass.

Terbinex NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Terbinex as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Terbinex API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Terbinex as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Terbinex and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Terbinex NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Terbinex suppliers with NDC on PharmaCompass.

Terbinex GMP

Terbinex Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Terbinex GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Terbinex GMP manufacturer or Terbinex GMP API supplier for your needs.

Terbinex CoA

A Terbinex CoA (Certificate of Analysis) is a formal document that attests to Terbinex's compliance with Terbinex specifications and serves as a tool for batch-level quality control.

Terbinex CoA mostly includes findings from lab analyses of a specific batch. For each Terbinex CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Terbinex may be tested according to a variety of international standards, such as European Pharmacopoeia (Terbinex EP), Terbinex JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Terbinex USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty